Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Palisade Bio logo — Late-stage biopharma company advancing therapies for acute a...

Palisade Bio

Late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications

Founded 2005 United States Carlsbad, United States 15 employees Post-IPO Debt Biopharma, Biotechnology +2

General Information

Company Name Palisade Bio
Founded Year 2005
Location United States Carlsbad, United States
Founders / Decision Makers
Team member
Employees 15
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Palisade Bio. To contact Palisade Bio, visit palisadebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Palisade Bio compare?

A PDF of Palisade Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Palisade Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Palisade Bio

Palisade Bio is a late-stage biopharma company focused on developing therapies for acute and chronic gastrointestinal (GI) complications. The company's lead program, PALI-2108, is a microbiota-activated PDE4 inhibitor prodrug being developed for moderate-to-severe ulcerative colitis, while its second lead program, PALI-1908, targets fibrostenotic Crohn’s Disease in preclinical development.

Founded in 2005, Palisade Bio is committed to identifying and developing therapeutics that protect the integrity of the intestinal barrier, believing that addressing this disruption can revolutionize disease treatment and elevate patient care standards.

At 02 May 2024, the company received a Post-IPO Debt investment. As a biopharma and biotechnology entity operating in the health care and wellness industries, Palisade Bio is positioned to make significant strides in addressing unmet medical needs within the GI space.

Business keywords: Biopharmaceuticals, Therapeutics, Drug Development, Gastrointestinal, Microbiota, Ulcerative Colitis, Crohn's Disease, Clinical-stage Development, Gastrointestinal Barrier Integrity, R&D, Microbiome, Fibrostenotic, PDE4 Inhibitor, Acute and Chronic GI Complications, Intestinal Barrier

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt Undisclosed -
02 May 2024
Post IPO Equity Undisclosed -
07 Sep 2023
Post IPO Equity Undisclosed -
04 Jan 2023
Post IPO Equity Undisclosed -
12 Aug 2022
Post IPO Equity Undisclosed -
06 May 2022
Post IPO Equity Undisclosed -
20 Aug 2021
Post IPO Equity Undisclosed -
17 Dec 2020
Post IPO Equity Undisclosed -
27 May 2020

Latest News

View All
Ipsen is no longer advancing Sutro’s ADC; Layoffs at Tune Therapeutics — Endpoints.news
Ipsen is no longer advancing Sutro’s ADC; Layoffs at Tune Therapeutics
Endpoints.news Aug 08, 2025

Palisade Bio Alternatives & Competitors

View All Alternatives
Palisade Bio vs
Entero Therapeutics (Nasdaq: ENTO)
Entero Therapeutics (Nasdaq: ENTO) United States

A biopharma company focused on the development of targeted, non-systemic therapies for gastrointesti...

Post-IPO Equity
12 employees
Biotechnology, Health Care
Palisade Bio vs
AM-Pharma
AM-Pharma The Netherlands

AM-Pharma’s ilofotase alfa is being developed as potential enzyme replacement therapy for adult hypo...

Venture round
31 employees
Biopharma, Biotechnology
Compare Palisade Bio vs AM-Pharma
Palisade Bio vs
Connect Biopharma
Connect Biopharma United States

Global Clinical Stage Company Connecting Patients with Innovation for Life

Series C
30 employees
Biotechnology, Health Care
View all alternatives

FAQ About Palisade Bio

Late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications
Palisade Bio was founded in 2005.
Palisade Bio is headquartered in Carlsbad, United States.
Palisade Bio operates in Biopharma, Biotechnology, Health Care and Health and Wellness. Its work centres on Biopharmaceuticals, Therapeutics, Drug Development and Gastrointestinal.
Palisade Bio has approximately 15 employees.
Palisade Bio has completed 8 funding rounds. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Palisade Bio include Entero Therapeutics (Nasdaq: ENTO), AM-Pharma, Connect Biopharma, Applied Molecular Transport, ClostraBio, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Palisade Bio and Entero Therapeutics (Nasdaq: ENTO) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Palisade Bio, https://bouncewatch.com/company/palisade-bio, updated 11 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes